KR20200050032A - Anti-inflammatory composition containing mixed extracts of fermented Gentianae scabrae Radix, Chrysanthemum indicum and Mentha piperascens - Google Patents
Anti-inflammatory composition containing mixed extracts of fermented Gentianae scabrae Radix, Chrysanthemum indicum and Mentha piperascens Download PDFInfo
- Publication number
- KR20200050032A KR20200050032A KR1020180131586A KR20180131586A KR20200050032A KR 20200050032 A KR20200050032 A KR 20200050032A KR 1020180131586 A KR1020180131586 A KR 1020180131586A KR 20180131586 A KR20180131586 A KR 20180131586A KR 20200050032 A KR20200050032 A KR 20200050032A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- gentian
- fermented
- chrysanthemum
- fermentation
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 148
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 27
- 240000005250 Chrysanthemum indicum Species 0.000 title claims description 52
- 235000018959 Chrysanthemum indicum Nutrition 0.000 title claims description 13
- 235000014435 Mentha Nutrition 0.000 title claims description 13
- 241001072983 Mentha Species 0.000 title claims description 13
- 241001071795 Gentiana Species 0.000 claims abstract description 76
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 44
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 230000036541 health Effects 0.000 claims abstract description 22
- 235000013376 functional food Nutrition 0.000 claims abstract description 20
- 229940105902 mint extract Drugs 0.000 claims abstract description 17
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 241000723353 Chrysanthemum Species 0.000 claims abstract 5
- 238000000855 fermentation Methods 0.000 claims description 40
- 230000004151 fermentation Effects 0.000 claims description 40
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 17
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 16
- 244000246386 Mentha pulegium Species 0.000 claims description 14
- 235000020737 peppermint extract Nutrition 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 12
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 12
- 235000001050 hortel pimenta Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 241001135871 Gentiana scabra Species 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 7
- -1 cleanser Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 7
- 230000003833 cell viability Effects 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 235000006679 Mentha X verticillata Nutrition 0.000 description 7
- 235000002899 Mentha suaveolens Nutrition 0.000 description 7
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 5
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- YRUMDWGUXBZEPE-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1.C1CCCCC1 YRUMDWGUXBZEPE-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940005627 gentian preparation Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 발효용담 추출물, 국화 추출물 및 박하 추출물을 함유하는 항염증용 약학적, 건강기능식품, 건강식품 및 화장료 조성물에 관한 것으로, 본 발명에 따른 상기 조성물은 발효용담 추출물과 국화 추출물 및 박하 추출물로 이루어진 군으로부터 선택되는 1종 이상의 추출물의 혼합 추출물을 함유함에 따라, 항염증 효능이 현저히 향상되는 효과가 있으며, 세포 생존율에 영향을 미치지 않아 부작용이 없으므로, 천연 항염증용 약학적, 건강기능식품, 건강식품 및 화장료 조성물로 유용하게 사용될 수 있다.The present invention relates to a pharmaceutical, health functional food, health food and cosmetic composition for anti-inflammatory containing fermented gentian extract, chrysanthemum extract and mint extract, wherein the composition according to the present invention is fermented gentian extract, chrysanthemum extract and mint extract As it contains a mixed extract of one or more extracts selected from the group consisting of, it has an effect of significantly improving the anti-inflammatory effect, and has no side effect because it does not affect cell viability, so it is a natural anti-inflammatory pharmaceutical and health functional food , It can be usefully used as a health food and cosmetic composition.
Description
본 발명은 발효용담 추출물, 국화 추출물 및 박하 추출물을 함유하는 항염증용 조성물에 관한 것으로, 구체적으로는 발효용담 추출물 및 국화 추출물 및 박하 추출물로 이루어진 군으로부터 선택되는 1종 이상의 추출물을 함유하는 항염증용 약학적, 건강기능식품, 건강식품 및 화장료 조성물에 관한 것이다.The present invention relates to an anti-inflammatory composition containing fermented gentian extract, chrysanthemum extract and mint extract, specifically, anti-inflammatory containing at least one extract selected from the group consisting of fermented gentian extract and chrysanthemum extract and mint extract. It relates to pharmaceutical, health functional food, health food and cosmetic composition.
염증은 외부의 물리·화학적 자극, 박테리아, 곰팡이, 바이러스, 각종 알레르기 유발 물질 등 외부 감염원의 감염에 대한 생체의 방어 반응이다. 염증 반응은 선천성 면역 반응의 일부이며, 다른 동물에서처럼 인간의 선천성 면역 반응은 대식세포가 병원체에 특이적으로 존재하는 세포 표면의 패턴을 통해 비자기(non-self)로 인식하고 공격함으로써 시작된다. 염증 반응 시에는 염증 부위에 혈장이 축적되어 세균이 분비한 독성을 희석시키며, 혈류가 증가하고, 홍반, 통증, 부종, 발열 등의 증상이 수반되게 된다.Inflammation is a body's defense response to infection from external infectious agents such as external physical and chemical stimuli, bacteria, fungi, viruses, and various allergens. The inflammatory response is part of the innate immune response, and as in other animals, the innate immune response in humans begins by recognizing and attacking non-self through macrophage-specific patterns of cell surfaces present in pathogens. During an inflammatory reaction, plasma accumulates in the inflamed area, diluting the toxicity secreted by bacteria, increasing blood flow, and accompanying symptoms such as erythema, pain, edema, and fever.
염증 반응에는 다양한 생화학적 현상이 관여하지만, 특히 대식세포(Macrophage)는 화학적 자극 등에 의하여 산화질소(NO)와 여러 염증성 사이토카인을 생성하여 염증반응에서 중요한 역할을 한다고 알려져 있다. 산화질소는 산화질소의 합성효소(nitric oxide synthase, NOS)의 작용에 의하여 L-아르기닌(L-arginine)으로부터 합성되는데, NOS는 몇 가지 이소 형태가 존재한다. 뇌에 존재하는 bNOS(brain NOS), 신경계에 존재하는 nNOS(neuronal NOS), 혈관 내피계에 존재하는 eNOS(endothelial NOS) 등은 체내에서 항상 일정수준으로 발현되고 있으며, 이들에 의해 소량 생성되는 일산화질소(NO)는 혈압 조절 작용, 신경 전달 작용, 학습, 기억 등과 관련된 다양한 생리 반응을 수행함으로써 인체의 항상성 유지에 중요한 역할을 수행한다. 이에 반하여 어떤 자극에 의하여 그 발현이 유도되는 iNOS(induced NOS)는 NO를 과다 생성하며, iNOS에 의해 과다 생성된 산화질소는 수퍼옥사이드(superoxide)와 반응하여 퍼옥시니트라이트(peroxynitrite)를 형성하고 이는 강력한 산화제로 작용하여 세포에 손상을 입힘으로써 염증과 암을 포함한 다양한 병리적 과정에 관여한다.Although various biochemical phenomena are involved in the inflammatory reaction, macrophages are known to play an important role in the inflammatory reaction by generating nitric oxide (NO) and various inflammatory cytokines by chemical stimulation. Nitric oxide is synthesized from L-arginine by the action of nitric oxide synthase (NOS), and NOS has several isoforms. BNOS (brain NOS) present in the brain, nNOS (neuronal NOS) present in the nervous system, and eNOS (endothelial NOS) present in the vascular endothelial system are always expressed at a certain level in the body, and a small amount of monoxide produced by them Nitrogen (NO) plays an important role in maintaining homeostasis by performing various physiological reactions related to blood pressure regulation, neurotransmission, learning, and memory. On the other hand, iNOS (induced NOS), whose expression is induced by a certain stimulus, generates excessive NO, and nitric oxide generated excessively by iNOS reacts with superoxide to form peroxynitrite. It acts as a powerful oxidant, damaging cells, thereby participating in various pathological processes, including inflammation and cancer.
한편, 용담(Gentiana scabra)은 용담과 용담속(Gentiana)에 속하는 여러해살이풀로 한국, 중국, 일본 등에 분포한다. 한방에서 용담(Gentianae scabrae Radix)은 용담의 뿌리 및 뿌리 줄기로서, 쓰고 차가운 성질로 청열조습(淸熱燥濕)하는 효능이 있다.Meanwhile, Gentiana scabra ) is a perennial plant belonging to Gentian and Gentian, distributed in Korea, China, and Japan. Oriental medicine (Gentianae scabrae Radix) is the root and rhizome of gentian, and has the effect of warm and humid with cold and cold properties.
국화(Chrysanthemum indicum)는 국화과 국화속 여러해살이풀로서 한국, 중국, 일본 등에 분포한다. 한방에서는 달고 쓰며 서늘한 성질로서 풍열사(風熱邪)를 제거하는 효능이 있어 종기 등 염증에 사용한다.Chrysanthemum ( Chrysanthemum indicum ) is a perennial plant of the Chrysanthemum family, distributed in Korea, China, and Japan. It is sweet, bitter and cool in oriental medicine, and has the effect of removing wind fever, which is used for inflammation such as boils.
박하(Mentha piperascens)는 꿀풀과 박하속 식물로 전세계적으로 분포한다. 한방에서는 맵고 서늘한 성질로 풍열사(風熱邪)로 인한 각종 병증에 사용된다.Peppermint ( Mentha piperascens ) is a herbaceous and peppermint plant distributed worldwide. In oriental medicine, it is a spicy and cool property and is used for various diseases caused by wind fever.
그러나 상기 용담, 국화 및 박하 모두를 혼합한 조성물의 항염증 효능에 관해서는 아직까지 연구된 바 없다. 이에 본 발명자들은 발효용담 추출물, 국화 추출물 및 박하 추출물을 혼합하여 사용하는 경우 항염증 효능이 현저히 증가되는 상승 작용이 나타남을 확인하여 본 발명을 완성하였다.However, the anti-inflammatory efficacy of the mixture of all of the gentian, chrysanthemum and peppermint has not been studied. Accordingly, the present inventors completed the present invention by confirming that a synergistic effect of remarkably increasing anti-inflammatory efficacy is exhibited when a mixture of fermented gentian extract, chrysanthemum extract, and mint extract is used.
본 발명의 목적은 항염증용 약학적, 건강기능식품, 건강식품 및 화장료 조성물을 제공하는 것이다.An object of the present invention is to provide a pharmaceutical, health functional food, health food and cosmetic composition for anti-inflammatory.
상기 목적을 달성하기 위하여,In order to achieve the above object,
본 발명은 발효용담 추출물; 및 국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고, 상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 약학적 조성물, 건강기능식품 조성물, 건강식품 조성물 및 화장료 조성물을 제공한다.The present invention is a fermented gentian extract; And Chrysanthemum ( Chrysanthemum indicum ) extract and peppermint ( Mentha piperascens ) extract; at least one selected from the group consisting of; containing, the fermentation gentian extract is gentian ( Gentiana It provides an anti-inflammatory pharmaceutical composition, health functional food composition, health food composition and cosmetic composition, characterized in that the extract is a fermented scabra ) yeast.
본 발명에 따른 발효용담 추출물, 국화 추출물 및 박하 추출물을 함유하는 항염증용 조성물은 발효용담 추출물과 국화 추출물 및 박하 추출물로 이루어진 군으로부터 선택되는 1종 이상의 추출물의 혼합 추출물을 함유함에 따라, 항염증 효능이 현저히 향상되는 효과가 있으며, 세포 생존율에 영향을 미치지 않아 부작용이 없으므로, 천연 항염증용 약학적, 건강기능식품, 건강식품 및 화장료 조성물로 유용하게 사용될 수 있다.The anti-inflammatory composition containing the fermented gentian extract, chrysanthemum extract and mint extract according to the present invention contains a mixed extract of fermented gentian extract and at least one extract selected from the group consisting of chrysanthemum extract and mint extract, anti-inflammatory It has the effect of significantly improving the efficacy, and has no side effect because it does not affect the cell viability, so it can be usefully used as a natural anti-inflammatory pharmaceutical, health functional food, health food and cosmetic composition.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
항염증용 약학적 조성물Pharmaceutical composition for anti-inflammatory
본 발명은 발효용담 추출물; 및 The present invention is a fermented gentian extract; And
국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고, Chrysanthemum indicum extract and peppermint ( Mentha) piperascens ) contains at least one extract selected from the group consisting of extracts;
상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 약학적 조성물에 관한 것이다.The fermentation gentian extract is gentian ( Gentiana scabra ) is a pharmaceutical composition for anti-inflammatory, characterized in that the extract is fermented with yeast.
본 발명에 따른 약학적 조성물에 있어서, 상기 효모는 사카로마이세스 세레비시아(Saccharomyces cerevisiae)인 것일 수 있다. 본 발명의 일실시예에서는 건조효모(Saccaromyces cerevisiae KCCM 11201)를 이용하여 상기 용담을 발효시켜 용담발효 추출물을 제조하였다.In the pharmaceutical composition according to the present invention, the yeast may be Saccharomyces cerevisiae . In an embodiment of the present invention, the gentian fermentation extract was prepared by fermenting the gentian using dry yeast ( Saccaromyces cerevisiae KCCM 11201).
본 발명에 따른 약학적 조성물에 있어서, 상기 발효용담은 용담(Gentiana scabra)의 뿌리를 이용하는 것일 수 있고, 상기 국화는 국화(Chrysanthemum indicum)의 꽃을 이용하는 것일 수 있으며, 상기 박하는 박하(Mentha piperascens)의 잎을 이용하는 것일 수 있으나, 이에 제한되지는 않는다.In the pharmaceutical composition according to the present invention, the fermentation gentian may be to use the root of the gentian ( Gentiana scabra ), the chrysanthemum may be to use the flowers of chrysanthemum ( Chrysanthemum indicum ), the peppermint peppermint ( Mentha piperascens ), but is not limited thereto.
본 발명에서 사용되는 용어 "추출물(extract)"은 추출 대상 원료를 그대로 또는 분쇄하여 적절한 용매를 사용하여 침출액으로 수득하고 침출액을 증발시켜 농축한 제제를 의미하는 것으로, 이에 제한되지는 않으나, 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물일 수 있다. 상기 추출물은 통상의 기술분야에 공지된 일반적인 추출방법, 분리 및 정제방법을 이용하여 제조할 수 있다. 상기 추출방법으로는, 이에 제한되지는 않으나, 바람직하게 용매 추출, 수증기 증류, 압착, 유지흡수, 휘발성 유기용제 추출, 또는 초임계 유체 추출, 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 방법을 사용할 수 있고, 바람직하게는 용매 추출 또는 수증기 증류의 방법을 사용하는 것일 수 있다. 이때 추출물을 수득하기 위해 사용할 수 있는 적절한 용매로는 당업계에서 허용되는 용매라면 어느 것을 사용해도 무방하며, 물 또는 유기용매를 사용할 수 있다. 예를 들어, 정제수, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등을 포함하는 탄소수 1 내지 4의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane) 및 시클로헥산(cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있으나, 이에 제한되지는 않는다. The term "extract" used in the present invention refers to a preparation obtained by extracting a raw material to be extracted as it is or pulverizing it using an appropriate solvent, and evaporating the leachate, but is not limited thereto. It may be an extract obtained by, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a crude product or a purified product thereof. The extract may be prepared using general extraction methods, separation and purification methods known in the art. The extraction method is not limited to this, but is preferably solvent extraction, water vapor distillation, compression, oil absorption, volatile organic solvent extraction, or supercritical fluid extraction, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction or ultrasonic Methods such as extraction may be used, and preferably, a method of solvent extraction or steam distillation may be used. At this time, any suitable solvent that can be used to obtain the extract may be any solvent acceptable in the art, and water or an organic solvent may be used. For example, alcohols having 1 to 4 carbon atoms, including purified water, methanol, ethanol, propanol, isopropanol, butanol, acetone, and ether , Benzene (benzene), chloroform (chloroform), ethyl acetate (ethyl acetate), methylene chloride (methylene chloride), hexane (hexane) and cyclohexane (cyclohexane) can be used alone or in combination, various solvents It is not limited.
바람직하게는 상기 국화 추출물 및 박하 추출물은 각각 물, 탄소수 1 내지 4개의 무수 또는 함수 저급 알코올, 다가 알코올, 탄화수소계 용매 또는 이들의 혼합용매로 구성된 군으로부터 선택되는 1종 이상의 추출용매를 사용하여 추출한 것일 수 있고, 더 바람직하게는 물 또는 탄소수 1 내지 4개의 무수 또는 함수 저급 알코올로부터 선택되는 1종 이상의 추출 용매를 사용하여 추출한 것일 수 있다.Preferably, the chrysanthemum extract and peppermint extract are each extracted using one or more extraction solvents selected from the group consisting of water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms, polyhydric alcohols, hydrocarbon-based solvents, or mixed solvents thereof. It may be, and more preferably, it may be extracted using one or more extraction solvents selected from water or anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms.
본 발명에 따른 약학적 조성물에 있어서, 상기 발효용담 추출물 및 국화 추출물 및 박하 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물을 1.0:0.1~3.0의 부피비로 포함하는 것일 수 있고, 바람직하게는 1.0:0.8~2.5의 부피비로 포함하는 것일 수 있다. 더 바람직하게는 발효용담 추출물 및 국화 추출물 또는 발효용담 추출물 및 박하 추출물을 각각 1:0.8~1.2의 부피비로 포함하거나 발효용담 추출물, 국화 추출물 및 박하 추출물을 1:0.8~1.2:0.8~1.2의 부피비로 포함하는 것일 수 있고, 발효용담 추출물 및 국화 추출물 또는 발효용담 추출물 및 박하 추출물을 각각 1:0.9~1.1의 부피비로 포함하거나 발효용담 추출물, 국화 추출물 및 박하 추출물을 1:0.9~1.1:0.9~1.1의 부피비로 포함하는 것이 특히 바람직하다.In the pharmaceutical composition according to the present invention, the fermentation gentian extract, and one or more extracts selected from the group consisting of chrysanthemum extract and mint extract may be included in a volume ratio of 1.0: 0.1 to 3.0, preferably 1.0: 0.8 It may be included in a volume ratio of ~ 2.5. More preferably, the fermentation gentian extract and the chrysanthemum extract or the fermentation gentian extract and the mint extract are each contained in a volume ratio of 1: 0.8 to 1.2, or the fermentation gentian extract, the chrysanthemum extract and the mint extract are in a volume ratio of 1: 0.8 to 1.2: 0.8 to 1.2, respectively. It may be to include, fermentation gentian extract and chrysanthemum extract or fermentation gentian extract and peppermint extract in a volume ratio of 1: 0.9 to 1.1 respectively, or fermentation gentian extract, chrysanthemum extract and mint extract 1: 0.9 to 1.1: 0.9 ~ It is particularly preferred to include it in a volume ratio of 1.1.
본 발명에 따른 약학적 조성물은 임상 투여시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있으며, 바람직하게는 경구 투여, 경피 투여, 국소 투여, 흡입 투여, 비강내 투여, 정맥내 투여, 진피내 투여, 복강내 투여, 주사 및 피하 주사용 제형으로 이루어진 군으로부터 선택되는 어느 하나 이상의 제형으로 투여되는 것일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 제조된다.The pharmaceutical composition according to the present invention may be administered in various dosage forms, oral and parenteral, during clinical administration, preferably oral administration, transdermal administration, topical administration, inhalation administration, intranasal administration, intravenous administration, intradermal administration It may be administered in any one or more formulations selected from the group consisting of administration, intraperitoneal administration, injection and subcutaneous injection formulations. When formulated, it is usually prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants.
경구투여를 위한 고형 제제에는 정제, 환자, 산제, 과립제, 캡슐제, 트로키제 등이 포함되며, 이러한 고형 제제는 하나 이상의 본 발명의 왕불류행 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로스(sucrose), 락토오스(lactose) 또는 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제 또는 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, patients, powders, granules, capsules, troches, etc. These solid preparations include at least one excipient such as starch, calcium carbonate in one or more of the present invention. It is prepared by mixing sucrose, lactose, or gelatin. In addition, lubricants such as magnesium stearate talc are used in addition to simple excipients. Liquid preparations for oral administration include suspending agents, intravenous solutions, emulsions or syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, flavoring agents, preservatives, etc. are included. Can be.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁용제, 유제, 동결건조제제, 좌제, 크림, 겔, 스프레이, 점적제(drops) 등이 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤, 젤라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspension solutions, emulsions, lyophilized preparations, suppositories, creams, gels, sprays, drops, and the like. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, etc. may be used.
본 발명의 약학적 조성물의 인체에 대한 효과적인 투여량은 환자의 나이, 몸무게, 성별, 투여형태, 건강상태 및 질환 정도에 따라 달라질 수 있으며, 일반적으로 약 0.01-1000 mg/kg/일이며, 바람직하게는 0.1-500 mg/kg/일 수 있고, 의사 또는 약사의 판단에 따라 일정시간 간격으로 1일 1회 내지 수회로 분할 투여할 수도 있다.The effective dosage for the human body of the pharmaceutical composition of the present invention may vary depending on the patient's age, weight, sex, dosage form, health status and disease level, and is generally about 0.01-1000 mg / kg / day, preferably It may be 0.1-500 mg / kg / day, and may be dividedly administered once to several times a day at regular time intervals according to the judgment of a doctor or pharmacist.
본 발명의 약학적 조성물은 유효성분으로서 발효용담 추출물, 국화 추출물 및 박하 추출물 이외에 공지된 항염증제를 추가로 포함할 수 있다.The pharmaceutical composition of the present invention may further include a known anti-inflammatory agent in addition to fermentation gentian extract, chrysanthemum extract and mint extract as an active ingredient.
항염증용 건강기능식품 및 건강식품 조성물Anti-inflammatory health functional food and health food composition
본 발명은 발효용담 추출물; 및 The present invention is a fermented gentian extract; And
국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고, Chrysanthemum indicum extract and peppermint ( Mentha) piperascens ) contains at least one extract selected from the group consisting of extracts;
상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 건강기능식품 조성물에 관한 것이다.The fermentation gentian extract is gentian ( Gentiana It relates to a health functional food composition for anti-inflammatory, characterized in that the extract is fermented with scabra ) yeast.
본 발명에서 사용되는 용어 "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 '기능성'이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 통상의 기술분야에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조시에는 통상의 기술분야에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한, 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한없이 제조될 수 있다. 본 발명의 건강기능식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 항염증제의 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The term "health functional food" used in the present invention refers to food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using ingredients or ingredients having useful functional properties for the human body. Here, the term 'functional' refers to obtaining a useful effect for health use, such as regulating nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be manufactured by a method conventionally used in the general technical field, and may be prepared by adding raw materials and components conventionally added in the general technical field. In addition, the formulation of the health functional food can also be prepared without limitation as long as the formulation is recognized as a health functional food. The health functional food composition of the present invention can be manufactured in various types of formulations, and has the advantage of not having side effects that may occur when taking the drug for a long time using food as a raw material, unlike general drugs, and has excellent portability. The health functional food of the present invention can be taken as an adjuvant to enhance the effectiveness of the anti-inflammatory agent.
또한, 본 발명은 발효용담 추출물; 및 In addition, the present invention is a fermented gentian extract; And
국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고, Chrysanthemum indicum extract and peppermint ( Mentha) piperascens ) contains at least one extract selected from the group consisting of extracts;
상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 건강식품 조성물에 관한 것이다.The fermentation gentian extract is gentian ( Gentiana scabra ) is an anti-inflammatory health food composition characterized in that it is an extract fermented with yeast.
본 발명의 조성물을 건강기능식품 조성물 또는 건강식품 조성물로 사용하는 경우, 상기 발효용담 추출물 및 국화 추출물 및 박하 추출물로부터 선택된 1종 이상의 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있고, 통상의 방법에 따라 적절하게 사용할 수 있다. 상기 조성물은 유효성분 이외에 식품학적으로 허용가능한 식품보조첨가제를 포함할 수 있으며, 유효성분의 혼합량은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다.When the composition of the present invention is used as a health functional food composition or a health food composition, one or more extracts selected from the fermentation gentian extract and chrysanthemum extract and peppermint extract can be added as it is or used with other foods or food ingredients, usually It can be used as appropriate according to the method. The composition may include a food additive that is food-acceptable in addition to the active ingredient, and the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment).
본 발명에서 사용되는 용어 "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품 또는 건강식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품보조첨가제의 종류가 제한되는 것은 아니다.The term "food supplement additive" used in the present invention means a component that can be supplementally added to food, and is added to prepare a health functional food or health food of each formulation, and can be appropriately selected and used by those skilled in the art. Examples of food supplements include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners , pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like, but the types of food supplements of the present invention are not limited by the examples.
또한, 본 발명의 조성물이 사용될 수 있는 건강기능식품 또는 건강식품의 종류에는 제한이 없다. 아울러 본 발명의 발효용담 추출물 및 국화 추출물 및 박하 추출물로부터 선택된 1종 이상의 추출물을 활성성분으로 포함하는 조성물은 당업자의 선택에 따라 건강기능식품에 함유될 수 있는 적절한 기타 보조 성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 추출물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다.In addition, there is no restriction on the type of health functional food or health food to which the composition of the present invention can be used. In addition, the composition comprising at least one extract selected from the fermented gentian extract and chrysanthemum extract and peppermint extract of the present invention as an active ingredient is mixed with other appropriate ingredients and known additives that may be contained in the health functional food according to the choice of those skilled in the art Can be produced. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, dairy products including gums, ice cream, various soups, beverages, teas, drinks, alcoholic beverages, and There are vitamin complexes and the like, and can be prepared by adding the extract according to the present invention as a main ingredient, and adding it to juice, tea, jelly, and juice.
항염증용 Anti-inflammatory 화장료Cosmetic 조성물 Composition
본 발명은 발효용담 추출물; 및 The present invention is a fermented gentian extract; And
국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고, Chrysanthemum indicum extract and peppermint ( Mentha) piperascens ) contains at least one extract selected from the group consisting of extracts;
상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 화장료 조성물에 관한 것이다.The fermentation gentian extract is gentian ( Gentiana It relates to a cosmetic composition for anti-inflammatory, characterized in that the extract is fermented with scabra ) yeast.
본 발명에 따른 화장료 조성물은 화장수, 영양로션, 영양크림, 수분크림, 마사지크림, 에센스, 페이스트, 마스크팩, 패치, 겔, 크림, 로션, 파우더, 비누, 클렌저, 오일, 파운데이션, 메이크업 베이스, 왁스 및 스프레이로 구성된 군으로부터 선택되는 1종 이상의 제형인 것일 수 있다. 상기한 성분 이외의 다른 성분들은 기타 제형 또는 사용 목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있다.The cosmetic composition according to the present invention includes lotion, nutrient lotion, nutrient cream, moisture cream, massage cream, essence, paste, mask pack, patch, gel, cream, lotion, powder, soap, cleanser, oil, foundation, makeup base, wax And it may be one or more formulations selected from the group consisting of spray. Other ingredients other than the above-mentioned ingredients may be appropriately selected and blended without difficulty by those skilled in the art according to other formulations or purpose of use.
상기 화장료 조성물은, 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 오일, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 또한, 포말(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다.The cosmetic composition may be, for example, a solution, gel, solid or dough anhydrous product, emulsion obtained by dispersing an oil phase in an aqueous phase, suspension, microemulsion, microcapsule, microgranule or ionic (liposome), nonionic vesicle dispersant It can be provided in the form of, cream, skin, lotion, oil, powder, ointment, spray or conceal stick. It can also be prepared in the form of a foam or aerosol composition further containing a compressed propellant.
또한, 상기 화장료 조성물은 본 발명의 상기 발효용담 추출물 및 국화 추출물 및 박하 추출물로부터 선택된 1종 이상의 추출물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 이들 보조제는 화장품학 분야에서 일반적으로 사용되는 양으로 도입된다.In addition, the cosmetic composition in addition to the at least one extract selected from the fermentation gentian extract and chrysanthemum extract and peppermint extract of the present invention, fat substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, Stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion blockers and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, It may contain adjuvants commonly used in the cosmetic field, such as hydrophilic or lipophilic actives, lipid vesicles, or any other ingredient commonly used in cosmetics. These supplements are introduced in amounts commonly used in the field of cosmetic science.
본 발명의 화장료 조성물에 있어서, 통상적으로 함유되는 화장료 조성물에 본 발명의 상기 발효용담 추출물 및 국화 추출물 및 박하 추출물로부터 선택된 1종 이상의 추출물이 0.1 내지 50 중량%, 바람직하게는 1 내지 10 중량%의 양으로 첨가될 수 있다.In the cosmetic composition of the present invention, one or more extracts selected from the fermentation gentian extract and the chrysanthemum extract and the peppermint extract of the present invention in a cosmetic composition that is usually contained is 0.1 to 50% by weight, preferably 1 to 10% by weight It can be added in an amount.
본 발명에 따른 발효용담 추출물 및 국화 추출물 및 박하 추출물로부터 선택된 1종 이상의 추출물을 피부 외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한, 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.When using at least one extract selected from fermentation gentian extract and chrysanthemum extract and peppermint extract according to the present invention as an external preparation for skin, additionally a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, a softening agent, an antioxidant, and a suspending agent , Stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion blockers and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments It may contain adjuvants commonly used in the field of skin science, such as, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients commonly used in external preparations for skin. In addition, the ingredients can be introduced in an amount commonly used in the field of dermatology.
본 발명에 따른 발효용담 추출물, 국화 추출물, 박하 추출물은 천연 식물을 원료로 하므로 약학적, 식품 또는 화장료 조성물로 사용할 경우에도 일반적인 합성 화합물에 비하여 부작용이 덜할 수 있으므로, 안전하게 약학적 조성물, 건강기능식품, 건강식품 및 화장료 조성물에 포함되어 유용하게 사용될 수 있다.Fermentation gentian extract, chrysanthemum extract, and peppermint extract according to the present invention use natural plants as a raw material, so even when used as a pharmaceutical, food or cosmetic composition, the side effects may be less than that of a general synthetic compound, so that the pharmaceutical composition, health functional food safely , It can be usefully included in health food and cosmetic compositions.
이하, 본 발명을 실시예에 의하여 더욱 상세하게 설명한다. 이들 실시예는 단지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail by examples. It will be apparent to those skilled in the art that these examples are merely for more specifically describing the present invention, and the scope of the present invention is not limited to these examples.
<< 제조예Manufacturing example 1> 1> 발효용담Fermentation Gentian 추출물의 제조 Preparation of extract
건조된 용담(Gentiana scabra Bunge) 뿌리(중국산, 휴먼허브) 50g, 정제수 500ml 및 건조효모 (Saccaromyces cerevisiae, 주식회사 조흥) 0.5g을 섞은 후, 30℃에서 100rpm으로 교반하며 24시간 배양하였다. 이를 여과지(Whatman No.1, USA)로 거른 후, 다시 0.2μm 필터(Sartorius, Germany)로 여과한 뒤 멸균하여 발효용담 추출물을 제조하였다.Dried gentian scabra Bunge) root (Chinese, Human Herb) 50g, purified water 500ml and dry yeast ( Saccaromyces cerevisiae , Choheung Co., Ltd.) 0.5g was mixed, followed by incubation at 30 ° C at 100 rpm for 24 hours. This was filtered through a filter paper (Whatman No. 1, USA), filtered again with a 0.2 μm filter (Sartorius, Germany), and sterilized to prepare an extract for fermentation.
<< 제조예Manufacturing example 2> 국화 추출물의 제조 2> Preparation of chrysanthemum extract
건조된 국화(Chrysanthemum indicum) 꽃(경북 영천, 휴먼허브) 50g을 정제수 500ml와 섞은 후, 80℃로 가열하여 1시간 동안 추출하였다. 이를 여과지 (Whatman No.1, USA)로 거른 후, 다시 0.2μm 필터(Sartorius, Germany)로 여과한 뒤 멸균하여 국화 추출물을 제조하였다.50 g of dried chrysanthemum ( Chrysanthemum indicum ) flowers (Yeongcheon, Gyeongbuk, Human Herb) were mixed with 500 ml of purified water, heated to 80 ° C and extracted for 1 hour. This was filtered through a filter paper (Whatman No. 1, USA), filtered again with a 0.2 μm filter (Sartorius, Germany), and sterilized to prepare a chrysanthemum extract.
<< 제조예Manufacturing example 3> 박하 추출물의 제조 3> Preparation of peppermint extract
건조된 박하(Mentha piperascens) 잎(경북 영천, 휴먼허브) 50g을 각각 정제수 500ml와 섞은 후, 80℃로 가열하여 1시간 동안 추출하였다. 이를 여과지 (Whatman No.1, USA)로 거른 후, 다시 0.2μm 필터(Sartorius, Germany)로 여과한 뒤 멸균하여 박하 추출물을 제조하였다.Dried mint ( Mentha piperascens ) 50 g of leaves (Yeongcheon, Gyeongbuk, and Human Hub) were mixed with 500 ml of purified water, respectively, and heated to 80 ° C to extract for 1 hour. This was filtered through a filter paper (Whatman No. 1, USA), filtered again with a 0.2 μm filter (Sartorius, Germany), and sterilized to prepare a mint extract.
<< 실험예Experimental Example 1> 세포 독성 측정 1> Cytotoxicity measurement
상기 제조예 1 내지 3의 방법으로 제조된 발효용담 추출물, 국화 추출물, 박하 추출물의 단독 추출물 및 2종 또는 3종의 추출물을 동일한 중량부로 혼합한 혼합 추출물에 대한 세포 독성을 평가하였다.Cytotoxicity was evaluated for a mixed extract obtained by mixing the fermented gentian extract, chrysanthemum extract, and peppermint extract alone and two or three extracts in the same parts by weight, prepared by the methods of Preparation Examples 1 to 3 above.
구체적으로, 마우스 대식세포주인 RAW264.7 세포(한국생명공학연구원)를 10% fetal bovine serum (Gibco, USA)가 함유된 DMEM 배지(Gibco, USA)를 이용하여 96well plate에 well당 5×104의 세포수로 분주하고 24시간 배양한 후, 단독 추출물 또는 혼합 추출물 시료가 첨가된 serum-free DMEM 배지로 교환하였다. 상기 각 시료의 처리는 하기 표 1에 나타난 바와 같이, 단독 추출물은 배지 전체 부피 대비 0.5%(v/v)로 처리하고, 2종 또는 3종의 추출물 배합 시에도 각 추출물을 0.5%(v/v)씩 혼합하여 처리하였다. 24시간 배양한 후, MTT(thiazolyl blue tetrazolium bromide, Sigma Aldrich, USA)를 PBS(phosphate-buffered saline)에 5mg/ml이 되도록 녹인 용액을 각 공에 20μl씩 넣은 후 3시간 더 배양하였다. 배지를 제거하고, DMSO(dimethyl sulfoxide, Amresco, USA)를 100μl씩 넣어 생성된 formazan crystal을 녹인 후, 마이크로플레이트 리더(Infinite F200, Tecan, Switzerland)를 이용하여 570nm에서 흡광도를 측정하였다.Specifically, 5 × 10 4 per well in a 96-well plate using DMEM medium (Gibco, USA) containing 10% fetal bovine serum (Gibco, USA) of mouse macrophage cell line RAW264.7 cells (Korea Research Institute of Bioscience and Biotechnology). After dispensing with the number of cells and cultured for 24 hours, the sample was exchanged with serum-free DMEM medium to which a single extract or a mixed extract sample was added. As shown in Table 1 below, the treatment of each sample was treated with 0.5% (v / v) of the total volume of the medium, and 0.5% (v / v) of each extract even when two or three extracts were combined. v) were mixed and treated. After incubation for 24 hours, 20 μl of each solution was dissolved in 5 mg / ml of MTT (thiazolyl blue tetrazolium bromide, Sigma Aldrich, USA) in phosphate-buffered saline (PBS), and then cultured for 3 hours. The medium was removed and DMSO (dimethyl sulfoxide, Amresco, USA) was added at 100 μl to dissolve the generated formazan crystal, and absorbance at 570 nm was measured using a microplate reader (Infinite F200, Tecan, Switzerland).
(제조예 1)Fermentation gentian extract
(Production Example 1)
(제조예 2)Chrysanthemum extract
(Production Example 2)
(제조예 3)Peppermint extract
(Production Example 3)
각 시료 처리에 따른 세포 생존율은 하기 식 1을 이용하여 확인하였으며, 그 결과를 하기 표 2에 나타내었다.Cell viability according to each sample treatment was confirmed using the following Equation 1, and the results are shown in Table 2 below.
[식 1][Equation 1]
세포 생존율(%) = A/B × 100Cell viability (%) = A / B × 100
(이때, A는 각 시료의 흡광도이고, B는 대조군(시료 무첨가)의 흡광도이다.)(A is the absorbance of each sample, and B is the absorbance of the control group (no sample added).)
상기 표 3에 나타난 바와 같이, 각 추출물을 0.5%로 단독 처리 또는 혼합 처리시 RAW264.7 세포의 생존율이 모두 100% 이상으로 나타나, 본 발명에 따른 발효용담 추출물, 국화 추출물, 박하 추출물 및 이들의 2종 또는 3종 혼합 추출물은 독성이 없음을 확인하였다.As shown in Table 3, the survival rate of RAW264.7 cells was 100% or more when each extract was treated with 0.5% alone or mixed, and the fermentation gentian extract, chrysanthemum extract, mint extract and their It was confirmed that the mixed extracts of 2 or 3 were not toxic.
<< 실험예Experimental Example 2> Nitric oxide(NO) 생성량 측정(항염증 활성 평가) 2> Nitric oxide (NO) production measurement (anti-inflammatory activity evaluation)
마우스 대식세포주인 RAW264.7 세포(한국생명공학연구원)를 10% fetal bovine serum이 함유된 DMEM 배지를 이용하여 96well plate에 well당 5×104의 세포수로 분주하고 24시간 배양한 후, 단독 추출물 또는 혼합 추출물 시료가 첨가된 serum-free DMEM 배지로 교환하였다. 상기 각 시료의 처리는 상기 실험예 1과 동일하게 상기 표 1에 나타난 바와 같이, 단독 추출물은 배지 전체 부피 대비 0.5%(v/v)로 처리하고, 2종 또는 3종의 추출물 배합 시에도 각 추출물을 0.5%(v/v)씩 혼합하여 처리하였다. 1시간 후 여기에 lipopolysaccharide(Sigma Aldrich, USA)를 1μg/ml이 되도록 첨가하고 24시간 배양하였다. 배지 60μl와 Griess reagent (Sigma Aldrich, USA) 60μl를 섞고 10분후 마이크로플레이트 리더(Infinite F200, Tecan, Switzerland)를 이용하여 570nm 흡광도 측정을 하였다. 각 시료 처리에 따른 NO 생성 저해율은 하기 식 2를 이용하여 확인하였으며, 그 결과를 하기 표 3에 나타내었다.After dispensing the mouse macrophage cell line RAW264.7 cells (Korea Research Institute of Bioscience and Biotechnology) with DMEM medium containing 10% fetal bovine serum, dispensing the cells into 96-well plates with 5 × 10 4 cells per well and incubating for 24 hours. The samples were exchanged with serum-free DMEM medium to which extract or mixed extract samples were added. As shown in Table 1, as in Experimental Example 1, the treatment of each sample was treated with 0.5% (v / v) of the total volume of the medium, and each of the two or three extracts was combined. The extracts were treated by mixing in 0.5% (v / v) increments. After 1 hour, lipopolysaccharide (Sigma Aldrich, USA) was added to 1 μg / ml and cultured for 24 hours. 60 μl of the medium and 60 μl of Griess reagent (Sigma Aldrich, USA) were mixed, and after 10 minutes, the absorbance was measured at 570 nm using a microplate reader (Infinite F200, Tecan, Switzerland). The inhibition rate of NO production according to each sample treatment was confirmed using Equation 2 below, and the results are shown in Table 3 below.
[식 2][Equation 2]
NO 생성 저해율 (%) = [1-(A/B)] × 100NO production inhibition rate (%) = [1- (A / B)] × 100
(이때, A는 각 시료의 흡광도이고, B는 대조군(시료 무첨가)의 흡광도이다.)(A is the absorbance of each sample, and B is the absorbance of the control group (no sample added).)
상기 표 4에 나타난 바와 같이, 발효용담 추출물, 국화 추출물 및 박하 추출물을 2종 또는 3종 혼합한 실시예 1 내지 3의 혼합 추출물은 모두 비교예 1 내지 3의 단독 추출물보다 높은 NO 생성 저해율을 나타내었고, 특히, 실시예 1의 발효용담, 국화 및 박하 추출물은 74.86%의 가장 높은 NO 생성 저해율을 나타내었다.As shown in Table 4, the mixed extracts of Examples 1 to 3 in which two or three types of fermented gentian extract, chrysanthemum extract and peppermint extract were mixed show higher NO production inhibition rate than the single extracts of Comparative Examples 1 to 3. In particular, the fermentation gentian, chrysanthemum and peppermint extract of Example 1 exhibited the highest inhibition rate of NO production of 74.86%.
따라서, 발효용담, 국화 및 박하 추출물을 혼합하면 항염증 활성에 대한 상승효과가 나타남을 확인하였고, 이로부터 상기 혼합추출물을 새로운 항염증용 조성물 및 피부진정 효능의 화장료 조성물로 유용하게 사용할 수 있음을 확인하였다.Therefore, it was confirmed that when the fermentation gentian, chrysanthemum and mint extract were mixed, a synergistic effect on anti-inflammatory activity appeared, from which the mixed extract can be usefully used as a new anti-inflammatory composition and skin soothing efficacy cosmetic composition. Confirmed.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, the present invention has been focused on the preferred embodiments. Those skilled in the art to which the present invention pertains will appreciate that the present invention may be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered in terms of explanation, not limitation. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent range should be interpreted as being included in the present invention.
Claims (9)
국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고,
상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 약학적 조성물.
Fermented gentian extract; And
Chrysanthemum indicum extract and peppermint ( Mentha) piperascens ) contains at least one extract selected from the group consisting of extracts;
The fermentation gentian extract is gentian ( Gentiana scabra ) is a pharmaceutical composition for anti-inflammatory, characterized in that the extract is fermented with yeast.
상기 효모는 사카로마이세스 세레비시아(Saccharomyces cerevisiae)인 것을 특징으로 하는 약학적 조성물.
According to claim 1,
The yeast is Saccharomyces Saccharomyces cerevisiae ).
상기 국화 추출물 및 박하 추출물은 각각 물, 탄소수 1 내지 4개의 무수 또는 함수 저급 알코올, 다가 알코올, 탄화수소계 용매 또는 이들의 혼합용매로 구성된 군으로부터 선택되는 1종 이상의 추출용매를 사용하여 추출한 것을 특징으로 하는 약학적 조성물.
According to claim 1,
The chrysanthemum extract and peppermint extract are each extracted using one or more extraction solvents selected from the group consisting of water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms, polyhydric alcohols, hydrocarbon-based solvents, or mixed solvents thereof. Pharmaceutical composition.
상기 발효용담 추출물 및 국화 추출물 및 박하 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물을 1.0:0.1~3.0의 부피비로 포함하는 것을 특징으로 하는 약학적 조성물.
According to claim 1,
A pharmaceutical composition comprising one or more extracts selected from the group consisting of the fermentation gentian extract and chrysanthemum extract and mint extract in a volume ratio of 1.0: 0.1 to 3.0.
상기 발효용담 추출물 및 국화 추출물 및 박하 박하 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물을 1.0:0.8~2.5의 부피비로 포함하는 것을 특징으로 하는 약학적 조성물.
The method of claim 4,
A pharmaceutical composition comprising at least one extract selected from the group consisting of the fermentation gentian extract and chrysanthemum extract and peppermint mint extract in a volume ratio of 1.0: 0.8-2.5.
국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고,
상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 건강기능식품 조성물.
Fermented gentian extract; And
Chrysanthemum indicum extract and peppermint ( Mentha piperascens ) contains at least one extract selected from the group consisting of extracts;
The fermentation gentian extract is gentian ( Gentiana scabra ) is a health functional food composition for anti-inflammatory, characterized in that the extract is fermented with yeast.
국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고,
상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 건강식품 조성물.
Fermented gentian extract; And
Chrysanthemum indicum extract and peppermint ( Mentha) piperascens ) contains at least one extract selected from the group consisting of extracts;
The fermentation gentian extract is gentian ( Gentiana scabra ) is a health food composition for anti-inflammatory, characterized in that the extract is fermented with yeast.
국화(Chrysanthemum indicum) 추출물 및 박하(Mentha piperascens) 추출물로 이루어진 군으로부터 선택된 1종 이상의 추출물;을 함유하고,
상기 발효용담 추출물은 용담(Gentiana scabra)을 효모로 발효시킨 추출물인 것을 특징으로 하는 항염증용 화장료 조성물.
Fermented gentian extract; And
Chrysanthemum indicum extract and peppermint ( Mentha) piperascens ) contains at least one extract selected from the group consisting of extracts;
The fermentation gentian extract is gentian ( Gentiana scabra ) cosmetic composition for anti-inflammatory, characterized in that the extract is fermented with yeast.
상기 화장료 조성물은 화장수, 영양로션, 영양크림, 수분크림, 마사지크림, 에센스, 페이스트, 마스크팩, 패치, 겔, 크림, 로션, 파우더, 비누, 클렌저, 오일, 파운데이션, 메이크업 베이스, 왁스 및 스프레이로 구성된 군으로부터 선택되는 1종 이상의 제형인 것을 특징으로 하는 화장료 조성물.The method of claim 8,
The cosmetic composition is a lotion, nutrition lotion, nutrition cream, moisture cream, massage cream, essence, paste, mask pack, patch, gel, cream, lotion, powder, soap, cleanser, oil, foundation, makeup base, wax and spray Cosmetic composition characterized in that it is one or more formulations selected from the group consisting of.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180131586A KR102177221B1 (en) | 2018-10-31 | 2018-10-31 | Anti-inflammatory composition containing mixed extracts of fermented Gentianae scabrae Radix, Chrysanthemum indicum and Mentha piperascens |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180131586A KR102177221B1 (en) | 2018-10-31 | 2018-10-31 | Anti-inflammatory composition containing mixed extracts of fermented Gentianae scabrae Radix, Chrysanthemum indicum and Mentha piperascens |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200050032A true KR20200050032A (en) | 2020-05-11 |
KR102177221B1 KR102177221B1 (en) | 2020-12-14 |
Family
ID=70729213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180131586A KR102177221B1 (en) | 2018-10-31 | 2018-10-31 | Anti-inflammatory composition containing mixed extracts of fermented Gentianae scabrae Radix, Chrysanthemum indicum and Mentha piperascens |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102177221B1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100800534B1 (en) * | 2007-08-27 | 2008-02-04 | 네비온 주식회사 | Anti-dandruff shampoo composition containing rhubarb extract, peppermint extract and Dead Sea mineral |
KR20090032586A (en) * | 2007-09-28 | 2009-04-01 | 경희대학교 산학협력단 | Pharmaceutical composition with anti-inflammatory, analgesic, antipyretic, antioxidant and antihistamine effects and preparation method thereof |
KR20100033573A (en) * | 2008-09-22 | 2010-03-31 | 성균관대학교산학협력단 | The composition for anti-oxidation or anti-inflammation comprising chrysanthemum extract and the method of preparation thereof |
KR20100066694A (en) * | 2008-12-10 | 2010-06-18 | (주)아모레퍼시픽 | Cosmetic composition containing moisturizing complex for moisturizing the skin |
KR100972116B1 (en) * | 2009-10-29 | 2010-07-23 | (주)한국파비스 알엔디 | Method of producing fermentation of herbal medicine, the fermentation produced thereby, and food comprising the fermentation |
KR20160005162A (en) * | 2014-07-03 | 2016-01-14 | 원광대학교산학협력단 | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease |
KR20170061756A (en) * | 2015-11-26 | 2017-06-07 | 재단법인 한국한방산업진흥원 | Method of preparing fermented extract of Gentiana scabra having increased antioxidant and anti-inflammatory activity, and the fermented extract |
KR101910156B1 (en) | 2016-10-26 | 2018-10-19 | 재단법인 제주테크노파크 | Anti-inflammatory Composition Using an Extract of Black Radish |
-
2018
- 2018-10-31 KR KR1020180131586A patent/KR102177221B1/en active IP Right Grant
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100800534B1 (en) * | 2007-08-27 | 2008-02-04 | 네비온 주식회사 | Anti-dandruff shampoo composition containing rhubarb extract, peppermint extract and Dead Sea mineral |
KR20090032586A (en) * | 2007-09-28 | 2009-04-01 | 경희대학교 산학협력단 | Pharmaceutical composition with anti-inflammatory, analgesic, antipyretic, antioxidant and antihistamine effects and preparation method thereof |
KR20100033573A (en) * | 2008-09-22 | 2010-03-31 | 성균관대학교산학협력단 | The composition for anti-oxidation or anti-inflammation comprising chrysanthemum extract and the method of preparation thereof |
KR20100066694A (en) * | 2008-12-10 | 2010-06-18 | (주)아모레퍼시픽 | Cosmetic composition containing moisturizing complex for moisturizing the skin |
KR100972116B1 (en) * | 2009-10-29 | 2010-07-23 | (주)한국파비스 알엔디 | Method of producing fermentation of herbal medicine, the fermentation produced thereby, and food comprising the fermentation |
KR20160005162A (en) * | 2014-07-03 | 2016-01-14 | 원광대학교산학협력단 | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease |
KR20170061756A (en) * | 2015-11-26 | 2017-06-07 | 재단법인 한국한방산업진흥원 | Method of preparing fermented extract of Gentiana scabra having increased antioxidant and anti-inflammatory activity, and the fermented extract |
KR101910156B1 (en) | 2016-10-26 | 2018-10-19 | 재단법인 제주테크노파크 | Anti-inflammatory Composition Using an Extract of Black Radish |
Non-Patent Citations (2)
Title |
---|
Anti-inflammatory and sedative-hypnotic activity of the methanolic extract of the leaves of mentha arvensis, Ancient Science of Life 2003 October, 23(2), pp.95-99(2003.12.) 1부.* * |
Chemical Composition and Anti-Inflammatory, Cytotoxic and Antioxidant Activities of Essential Oil from Leaves of Mentha piperita Grown in China, PLOS ONE, 2014.11.10. * |
Also Published As
Publication number | Publication date |
---|---|
KR102177221B1 (en) | 2020-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9682029B2 (en) | Ceramide production enhancer and moisturizer | |
KR102322782B1 (en) | Compositions for reinforcing skin barrier and improving atopic dermatitis using an extract of wild edible greens as an active ingredient | |
KR20180077927A (en) | Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof | |
KR102299277B1 (en) | Composition for improving scalp condition comprising flower extract of passiflora edulis | |
KR100999870B1 (en) | Pharmaceutical composition for preventing and treating allergic skin diseases, containing Echo and Elm extract as active ingredients | |
KR101964249B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising mixture of Torilis japonica extract and copper tripeptide-1 as effective component | |
KR100991399B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases, which contains Eungseongcho, Geumchocho, Chajeoncho, Elm and upper leaf mixed extract as active ingredients | |
KR102228257B1 (en) | Composition for anti-inflammation or anti-acne comprising extract of Immature Citrus Fruit, Curcuma longa and citrus blossom honey | |
JP6059510B2 (en) | Ceramide production promoter | |
KR102179610B1 (en) | Composition for preventing hair loss or promoting hair growth containing essential oil mixture of Coicis semen and Evening Primrose seeds | |
KR20170055758A (en) | Anti inflammatory comprising plant extract | |
KR102142461B1 (en) | Composition for improving skin condition comprising extract of korean fir | |
KR102343245B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Chrysanthemum indicum L. oil extract as effective component | |
KR102177221B1 (en) | Anti-inflammatory composition containing mixed extracts of fermented Gentianae scabrae Radix, Chrysanthemum indicum and Mentha piperascens | |
KR102577528B1 (en) | Composition for improving skin | |
KR102012366B1 (en) | Composition for whitening comprising Withania somnifera callus extract | |
KR101419587B1 (en) | Composition for Promoting Regeneration of Skin Comprising Ginseng Oil as Active Ingredient | |
KR20100133090A (en) | Composition for the prevention and treatment of atopy containing Cudrania japonica extract as an active ingredient | |
KR20150144688A (en) | Composition for improving scalp condition comprising extract of passiflora incarnate | |
KR102274305B1 (en) | Composition for improving scalp condition comprising flower extract of passiflora laurifolia | |
KR102675988B1 (en) | Composition for improving skin containing 3,3',4-tri-O-methylellagic acid as an active ingredient | |
JP6022333B2 (en) | Ceramide production promoter | |
KR102198355B1 (en) | Pharmaceutical composition comprising Cymbidium extracts for preventing or treating allergic diseases or contact | |
JP6151027B2 (en) | Ceramide production promoter | |
KR20230058205A (en) | Pharmaceutical composition for preventing or treating hair loss comprising coix seed extract and minoxidil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20181031 |
|
PA0201 | Request for examination | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191219 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200527 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200804 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20201203 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20201204 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20231025 Start annual number: 4 End annual number: 4 |